Swiss biopharma selling antifungal and antibacterial hospital drugs, led by Cresemba and Zevtera.
Swiss biopharma selling antifungal and antibacterial hospital drugs, led by Cresemba and Zevtera.
Much of the income comes as royalties and milestone payments from licensing partners that market Cresemba in their regions, plus supply of the drug to them, rather than from its own sales force. Zevtera follows a similar route through regional distributors.
In one line: A small Swiss anti-infectives specialist.
Moat: narrow (IP / patents, regulatory licence). Patent-protected hospital anti-infectives approved and marketed across multiple markets.
Headquarters: Basel, Switzerland · Founded: 2000 · Employees: 189
Size Basilea Pharmaceutica (BSLN.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $1.04B, the 120th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 71.50 on 18 Nov 2026.
Performance Over six months the shares gained 33.4%, against -10.6% for the median peer and +9.3% for the Switzerland market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 4.7% over the last twelve months (peer median +3.1%); the operating margin is 23.9% (peer median 8.0%).
Valuation It trades at 10.5× forward earnings against a peer median of 16.2× (5th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 63.0 points above its cost of capital (5.0% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 247M | CHF 232M | CHF 209M | CHF 158M | CHF 148M |
| Revenue growth | — | +11% | +32% | +7% | — |
| Gross profit | CHF 217M | CHF 193M | CHF 170M | CHF 131M | CHF 121M |
| EBITDA | CHF 63.6M | CHF 55.3M | CHF 64.7M | CHF 22.7M | CHF 19.4M |
| Net income | CHF 52.4M | CHF 40.2M | CHF 77.6M | CHF 10.5M | CHF 12.1M |
| Free cash flow | CHF 55.3M | CHF 59.5M | CHF 72.7M | CHF 13.4M | CHF 3.92M |
| Capital expenditure | CHF 2.89M | CHF 2.86M | CHF 1.79M | CHF 1.03M | CHF 3.30M |
| Total debt | n/a | CHF 89.2M | CHF 112M | CHF 129M | CHF 187M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Basilea Pharmaceutica BSLN.SW | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| Merck & MRK | $340B | +23% | +5% | 18% | 16.4× | 8.3% |
| Gilead Sciences GILD | $210B | +30% | +7% | 38% | 19.9× | -2.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BSLN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.9% | -5.9% | 3rd highest of 21 |
| 6-month return | +33.4% | -10.6% | highest of 21 |
| Distance from 52-week high | -5.7% | -32.1% | 2nd highest of 21 |
| Revenue growth (TTM) | +4.7% | +3.1% | 9th highest of 18 |
| Operating margin | 23.9% | 8.0% | 4th highest of 19 |
| Forward P/E | 10.5× | 16.2× | 5th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -5.6% | 2.3% | 3rd least demanding of 14 |
| Growth delivered (Del g) | +12.7% | +4.2% | 4th highest of 14 |
| Hurdle (Req g minus delivered) | -18.3 pp | -3.3 pp | 2nd least demanding of 14 |
| ROIC minus cost of capital | +63.0 pp | +0.1 pp | highest of 19 |
| EV / EBITDA | 12.4× | 7.3× | 2nd most expensive of 5 |
| Net debt / EBITDA | -1.4× | -1.3× | 3rd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | n/a | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% | +4.2% |